Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: Eur J Pharm Sci. 2017 Aug 1;109:78–85. doi: 10.1016/j.ejps.2017.07.031

Figure 1. Study flowcharts related to the Experiment 1 (A) and Experiment 2 (B).

Figure 1

A) Experiment 1, Eighty-eight participants were screened and 48 healthy male volunteers (N = 48) were randomized into six groups of eight participants, six to receive GET 73 and two to receive placebo. B) Experiment 2, Fifty-nine participants were screened and 32 healthy male volunteers (N = 32) were randomized into four groups of eight participants, six to receive GET 73 and two to receive placebo. Individuals in groups 1 - 3 received 14 doses according to the randomization schedule, while individuals in group 4 received 28 doses. All groups were dosed sequentially with escalation to the next dose following review of emerging safety and tolerability data.